Taiwan
· Delayed Price · Currency is TWD Caliway Biopharmaceuticals Statistics
Total Valuation
Caliway Biopharmaceuticals has a market cap or net worth of TWD 92.22 billion. The enterprise value is 82.54 billion.
| Market Cap | 92.22B |
| Enterprise Value | 82.54B |
Important Dates
The next estimated earnings date is Wednesday, March 5, 2025.
| Earnings Date | Mar 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Caliway Biopharmaceuticals has 153.44 million shares outstanding. The number of shares has increased by 10.76% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 153.44M |
| Shares Change (YoY) | +10.76% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 24.43% |
| Owned by Institutions (%) | 0.02% |
| Float | 111.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 9.48 |
| P/TBV Ratio | 9.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -126.78 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -134.08 |
Financial Position
The company has a current ratio of 149.70, with a Debt / Equity ratio of 0.00.
| Current Ratio | 149.70 |
| Quick Ratio | 149.34 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -1,873.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +206.93% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +206.93% |
| 50-Day Moving Average | 555.48 |
| 200-Day Moving Average | 515.92 |
| Relative Strength Index (RSI) | 55.02 |
| Average Volume (20 Days) | 947,093 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Caliway Biopharmaceuticals had revenue of TWD 49.98 million and -651.00 million in losses. Loss per share was -4.78.
| Revenue | 49.98M |
| Gross Profit | 34.67M |
| Operating Income | -700.55M |
| Pretax Income | -651.00M |
| Net Income | -651.00M |
| EBITDA | -679.48M |
| EBIT | -700.55M |
| Loss Per Share | -4.78 |
Balance Sheet
The company has 9.69 billion in cash and 14.07 million in debt, giving a net cash position of 9.68 billion or 63.09 per share.
| Cash & Cash Equivalents | 9.69B |
| Total Debt | 14.07M |
| Net Cash | 9.68B |
| Net Cash Per Share | 63.09 |
| Equity (Book Value) | 9.73B |
| Book Value Per Share | 63.42 |
| Working Capital | 9.66B |
Cash Flow
In the last 12 months, operating cash flow was -603.38 million and capital expenditures -12.20 million, giving a free cash flow of -615.58 million.
| Operating Cash Flow | -603.38M |
| Capital Expenditures | -12.20M |
| Free Cash Flow | -615.58M |
| FCF Per Share | -4.01 |
Margins
| Gross Margin | 69.37% |
| Operating Margin | -1,401.74% |
| Pretax Margin | -1,302.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Caliway Biopharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.76% |
| Shareholder Yield | -10.76% |
| Earnings Yield | -0.80% |
| FCF Yield | -0.67% |
Stock Splits
The last stock split was on March 21, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Mar 21, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |